A Simple Clustering Technique to Improve QSAR Model Selection and Predictivity: Application to a Receptor Independent 4D-QSAR Analysis of Cyclic Urea Derived Inhibitors of HIV-1 Protease

Journal of Chemical Information and Computer Sciences

Volumn 43, Issue 6, 2003, Pages 2180-2193

  Senese, Craig L ^a   Hopfinger, A J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTER ANALYSIS; FLUORESCENT SUBSTRATES;

ALGORITHMS; COMPUTATIONAL METHODS; CORRELATION METHODS; ENZYMES; FLUORESCENCE; MORPHOLOGY; UREA; VIRUSES;

DRUG THERAPY;

DRUG DERIVATIVE; PROTEINASE INHIBITOR; UREA;

ALGORITHM; ARTICLE; ARTIFICIAL INTELLIGENCE; CHEMICAL STRUCTURE; CHEMISTRY; CLUSTER ANALYSIS; DRUG EFFECT; ENZYMOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; KINETICS; PREDICTION AND FORECASTING; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REPRODUCIBILITY;

ALGORITHMS; ARTIFICIAL INTELLIGENCE; CLUSTER ANALYSIS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; KINETICS; MODELS, MOLECULAR; PREDICTIVE VALUE OF TESTS; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRODUCIBILITY OF RESULTS; UREA;

EID: 0344686399     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci034168q     Document Type: Article

References (27)

1. Roberts, N. A.; Craig, J. C.; Duncan, I. B. HIV proteinase inhibitors. Bio. Soc. Trans. 1992, 20, 513-516.
2. Sakurai, M.; Sugano, M.; Handa, H.; Komai, T.; Yagi, R.; Nishigaki, T.; Yabe, Y. Studies of HIV-1 protease inhibitors. I. Incorporation of a reduced peptide, simple amino alcohol, and Staline analogue at the scissile site of substrate sequences. Chem. Pharm. Bull. 1993, 41, 1369-1377.
3. Kaldor, S. W.; Kalish, V. J.; Davies, J. F.; Shetty, B. V.; Fritz, J. E. ; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; Dressman, B. A.; Hatch, S. D.; Khalil, D. A.; Kosa, M. B.; Lubbehusen, P. P.; Muesing, M. A.; Patrick, A. K.; Reich, S. H.; Su, K. S.; Tatlock, J. H. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 1997, 40, 3979-3985.
4. De Lucca, G. V.; Liang, J.; Aldrich, P. E.; Calabrese, J.; Cordova, B.; Klabe, R. M.; Rayner, M. M.; Chang, C.-H. Design, synthesis and evaluation of tetrahydropyrimidines as an example of a general approach to nonpeptide HIV protease inhibititors. J. Med. Chem. 1997, 40, 1707-1719.
5. Gupta, S. P.; Babu, M. S. Quantitative structure-activity relationship studies on cyclic cyanoguanidines acting as HIV protease inhibitors. Bioorg. Med. Chem. 1999, 7, 2549-2553.
6. Hagen, S. E.; Domagala, J.; Gajda, C.; Lovdahl, M.; Tait, B. D.; Wise, E.; Holler, T.; Hupe, D.; Nouhan, C.; Urumov, A.; Zeikus, G.; Zeikus, E.; Lunney, E. A.; Pavlovsky, A.; Gracheck, S. J.; Saunders, J.; VanderRoest, S.; Brodfuehrer, J. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters. J. Med. Chem. 2001, 44, 2319-2332.
7. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Meimbach, J. C. ; Dixon, R. A. F.; Scolnick, E. M.; Sigal, I. S. Active human immunodeficiency virus is required for viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 1998, 85, 4686-4690.
8. Ashorn, P.; McQuade, T. J.; Thaisrivongs, S.; Tomasselli, A. G.; Tarpley, W. G.; Moss, B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 7472-7476.
9. McQuade, T. J.; Tomasselli, A. G.; Liu, L.; Karacostas, V.; Moss, B.; Sawyer, T. K.; Heinrikson, R. L.; Ratpley, W. G. A synthetic HIV-1 protease inhibitor with antiviral, activity arrests HIV-like particle maturation. Science 1990, 247, 454-456.
10. Sakurai, M.; Higashida, S.; Sugano, M.; Komai, T.; Yagi, R.; Ozawa, Y.; Handa, H.; Nishigaki, T.; Yabe, Y. Structure-activity relationships of HIV-1 PR inhibitors containing AHPBA. Bioorg. Med. Chem. 1994, 2, 807-825.
11. Huang, X.; Xu, L.; Luo, X.; Fan, K.; Ji, R.; Pei, G.; Chen, K.; Jiang, H. Elucidating the inhibiting mode of AHPBA derivatives against HIV-1 protease and building predictive 3D-QSAR models. J. Med. Chem. 2002, 45, 333-343.
12. Senese, C. L.; Hopfinger, A. J. Receptor independent 4D-QSAR analysis of a set of norstatine derived inhibitors of HIV-1 protease. J. Chem. Inf. Comput. Sci. 2003, 43, 1297-1307.
13. Barnard, J. M.; Downs, G. M. Clustering of chemical structures on the basis of two-dimensional similarity measures. J. Chem. Inf. Comput. Sci. 1992, 32, 644-649.
14. Fan, Y.; Leming, M. S.; Kohn, K. W.; Pommier, Y.; Weinstein, J. N. Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm based studies. J. Med. Chem. 2001, 44, 3254-3263.
15. Brown, R. D.; Martin, Y. C. Use of structure-activity data to compare structure-based clustering methods and descriptors for use in compound selection. J. Chem. Inf. Comput. Sci. 1996, 36, 572-584.
16. McFarland, J. W.; Gans, D. J. Cluster significance analysis contrasted with three other quantitative structure-activity relationship methods. J. Med. Chem. 1987, 30, 46-49.
17. Downs, G. M.; Barnard, J. M. Rev. Comput. Chem. 2002, 18, 1-40.
18. Nair, A. C.; Jayatilleke, P.; Wang, X.; Miertus, S.; Welsh, W. J. Computational studies of tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor and receptor based properties. J. Med. Chem. 2002, 45, 973-983.
19. DeLucca, G. V.; Liang, J.; DeLucca, I. Stereospecific synthesis, structure-activity relationship and oral bioavailability of tetrahydropyrimidine-2-one HIV protease inhibitors. J. Med. Chem. 1999, 42, 135-152.
20. DeLucca, G. V.; Liang, J.; Aldrich, P. E.; Calabrese, J.; Cordova, B.; Klabe, R. M.; Rayner, M. M.; Chang, C.-H. Design, synthesis and evaluation of tetrahydropyirimidinones as an example of a general approach to nonpeptide HIV protease inhibitors. J. Med. Chem. 1997, 40, 1707-1719.
21. Hopfinger, A. J.; Wang, S.; Tokarski, J. S.; Jin, B.; Albuquerque, M.; Madhav, P. J.; Duraiswami, G. Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J. Am. Chem. Soc. 1997, 119, 10509-10524.
22. 4D-QSAR, Version 3.0; The Chem21 Group, Inc., 1780 Wilson Drive, Lake Forest, IL 60045, 2002.
23. Pan, D.; Tseng, Y.; Hopfinger, A. J. Quantitative Structure-Based Design: Formalism and Application of Receptor-Dependent RD-4D-QSAR Analysis to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase. J. Chem. Inf. Comput. Sci. 2003, publication in progress.
24. HyperChem Program Release 6.01 for Windows; Hypercube, Inc.; 2000.
25. MOLSIM V3.0; D. C. Doherty and The Chem21 Group, Inc., 1780 Wilson Drive, Lake Forest IL 60045, 1998.
26. Rogers, D.; Hopfinger, A. J. Application of the genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J. Chem. Inf. Comput. Sci. 1994, 34, 854-866.
27. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.